Trial to Study Treatment of Geographic Atrophy with Emixustat Hydrochloride

May 7, 2014

Emixustat Hydrochloride is an orally dosed compound produced by Acucela in development for the treatment of geographic atrophy (GA) associated with dry age-related macular degeneration (AMD).

Recently published to were details of a multi-center, randomized, masked, multiple-dose, crossover study of the pharmacokinetics of emixustat hydrochloride in subjects with GA associated with dry AMD.

Click here for details.




Jump down to form below to submit your own comments

Comments are closed.